The present study found that TNBC and HER2+ breast cancer patients have a high abundance of TILs infiltration, mainly immune infiltrated, while luminal breast cancer patients have a low abundance of TILs infiltration, mainly immune desert and immune excluded, further suggesting that the tumor immune microenvironment of breast cancer patients may affect the efficacy of neoadjuvant chemotherapy. Here, ERBB2 is linked to neoplasm.